Dr. David Sidransky Appointed to Orgenesis' Board of Directors
July 18 2013 - 1:00PM
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a
development-stage company with a novel therapeutic technology
dedicated to converting a patient's own liver cells into
functioning insulin-producing cells as a treatment for diabetes, is
pleased to announce the appointment of Dr. David Sidransky,
Professor and Director of the Head and Neck Cancer Research
Division at the Johns Hopkins University School of Medicine's
Department of Otolaryngology, to its Board of Directors.
Dr. Sidransky is a renowned oncologist and research scientist
named and profiled by TIME magazine in 2001 as one of the top
physicians and scientists in America, recognized for his work with
early detection of cancer. Since 1994, Dr. Sidransky has been the
Director of the Head and Neck Cancer Research Division at Johns
Hopkins University School of Medicine's Department of
Otolaryngology and Professor of Oncology, Cellular & Molecular
Medicine, Urology, Genetics, and Pathology at the John Hopkins
University School of Medicine. Dr. Sidransky is one of the most
highly cited researchers in clinical and medical journals in the
world in the field of oncology during the past decade, with over
460 peer-reviewed publications. Dr. Sidransky is a founder of a
number of biotechnology companies and holds numerous biotechnology
patents.
Dr. Sidransky has served as Vice Chairman of the Board of
Directors, and was, until the merger with Eli Lilly, a director of
ImClone Systems, Inc., a global biopharmaceutical company committed
to advancing oncology care. He is serving or has served on the
scientific advisory boards of MedImmune, Roche, Amgen and Veridex,
LLC (a Johnson & Johnson diagnostic company), among others, and
is currently on the board of KV Pharmaceutical, Rosetta Genomics
and Champions Oncology, Inc. Dr. Sidransky served as Director
(2005-2008) of the American Association for Cancer Research (AACR).
He was the chairperson of AACR International Conferences (2006 and
2007) on Molecular Diagnostics in Cancer Therapeutic Development:
Maximizing Opportunities for Personalized Treatment. Dr. Sidransky
is the recipient of a number of awards and honors, including the
1997 Sarstedt International Prize from the German Society of
Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking
and Health by the American College of Chest Physicians, and the
2004 Richard and Hinda Rosenthal Award from the American
Association of Cancer Research.
"We are truly honored to have a scientist and business leader of
Dr. Sidransky's stature join our team," said Orgenesis Chairperson,
Vered Caplan. "David brings a tremendous wealth of academic,
executive management and corporate government experience to
Orgenesis. His broad network of industry and government contacts,
combined with his special knowledge of genomics and cell-based
therapies, will be particularly invaluable to our success as we
work to answer the longstanding call for a solution to restore
normal insulin production in people with diabetes."
About Orgenesis Inc.
Orgenesis (OTCBB:ORGS) is a development stage company with a
novel therapeutic technology that employs a molecular and cellular
approach directed at converting a patient's own liver cells into
functional insulin producing cells, as a treatment for diabetes.
The Company believes that converting the diabetic patient's own
tissue into insulin-producing cells overcomes the problem of donor
shortage and removes the risk of transplant rejection. If
successful, this could mean the end of diabetes, as we now know it.
For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements"
which are not purely historical. Such forward-looking statements
include, among other things, the expectations of management that
our regeneration technology can be developed as therapeutic
treatment for diabetes. No assurance can be given that any of the
events anticipated by the forward-looking statements will occur or,
if they do occur, what benefits the Company will obtain from them.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
new projects and development stage companies, which include,
without limitation, the potential failure of development candidates
to advance through preclinical studies or demonstrate safety and
efficacy in clinical testing and the ability to pass clinical
trials so as to move on to the next phase, our ability to retain
key employees and our ability to finance development or satisfy the
rigorous regulatory requirements for new medical procedures.
Competitors may develop better or cheaper alternatives to our
products. These forward-looking statements are made as of the date
of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Investors should refer to the risk factors disclosure
outlined in our periodic reports filed from time-to-time with the
Securities and Exchange Commission.
On Behalf of the Board Orgenesis Inc.
Vered Caplan, Chairperson
CONTACT: Investor Contact:
Stephen Kilmer
Kilmer Lucas Inc.
T: 212-618-6347
stephen@kilmerlucas.com
Media Contact:
Leonard Zehr
Kilmer Lucas Inc.
T: (416) 833-9317
leonard@kilmerlucas.com
Orgenesis (QX) (USOTC:ORGS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Orgenesis (QX) (USOTC:ORGS)
Historical Stock Chart
From Dec 2023 to Dec 2024